Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery development and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras or PROTAC® targeted protein degraders that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs including ARV-102 targeting LRRK2 for neurodegenerative diseases ARV-806 targeting KRAS G12D for mutated cancers including pancreatic colorectal and non-small cell lung cancers ARV-393 targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma ARV-027 targeting the polyglutamine-expanded androgen receptor or polyQ-AR in skeletal … Sign In to View